Latest Investor Confidence News

Stellar Resources has raised $22.1 million through a placement led by Metals X, boosting its cash reserves to $33 million and setting the stage for key feasibility studies at Heemskirk.

AdAlta has secured A$2.5 million in a strategic placement to push its lead CAR-T therapy BZDS1901 through critical US FDA regulatory steps and establish Australian manufacturing, building on promising clinical responses in advanced mesothelioma.

Australian Mines Limited has raised $3 million through a strategic placement led by Tribeca Investment Partners to fast-track its Flemington Scandium Project from scoping to pre-feasibility study, aiming to de-risk and advance permitting.

Botala Energy Ltd has denied holding undisclosed information following a sharp share price rise, linking the spike to a recent Serowe CBM Project announcement and confirming compliance with ASX disclosure rules.

Avira Resources has cleared all major regulatory and heritage hurdles to kick off a 4,500-metre RC drilling campaign at its high-grade Mt Cattlin Gold Project, aiming for a maiden resource estimate by year-end.

Merino & Co. reported Q3 FY26 revenue of A$441,558 with new domestic and China purchase orders supporting its growth strategy, while cash reserves fell to A$654,282 due to investments in production and marketing.

Scentre Group has successfully tendered nearly 90% of its US$1.312 billion Non-Call 2030 Subordinated Notes, enabling full redemption and bolstering liquidity to A$3.2 billion. The group maintains its 2026 growth targets amid geopolitical uncertainty.

Kaili Resources has reported encouraging rare earth element assay results from its South Australian tenements, particularly within the Coodalya Mallee Project, while securing extended related-party financing to support ongoing exploration.

Omni Bridgeway reports strong investment activity and a robust pipeline for Q3 2026, maintaining solid returns and cost discipline amid global market volatility.

BlinkLab has completed onboarding all clinical sites for its pivotal FDA autism trial, enrolled the first participant, and launched a nationwide autism screening program in Morocco. A recent A$17.7 million capital raise will fund further trials and expansion into ADHD diagnostics.

Starpharma has confirmed FDA alignment for its DEP® HER2 first-in-human phase 1 trial, with preparations underway for a mid-2026 start. The biotech also progressed strategic partnerships, published promising data with Genentech, and reported a $14.1 million cash balance alongside rising Viraleze™ sales.

Toubani Resources has kicked off construction at its Kobada Gold Project in Mali following a positive Final Investment Decision, while securing a US$83.5 million financing package to support development.